<DOC>
	<DOCNO>NCT02404805</DOCNO>
	<brief_summary>The investigator believe simeprevir concentration unchanged administer combination dolutegravir relative administration alone . The investigator believe dolutegravir concentration unchanged administer combination simeprevir . Additionally , investigator believe simeprevir dolutegravir safe administer alone combination .</brief_summary>
	<brief_title>Drug Interaction Potential Between Dolutegravir Simeprevir HIV/HCV Seronegative Volunteers</brief_title>
	<detailed_description>To investigate potential drug interaction simeprevir dolutegravir , participant receive drug alone drug combination 7 day . The pharmacokinetics simeprevir dolutegravir give combination vs. alone compare .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Men woman age 1860 year Absence HIV1 HCV antibody screen , Ability willingness give write informed consent first trialrelated activity . Pregnancy Breastfeeding Active alcohol drug abuse , opinion investigator , would interfere adherence study requirement Participation investigational drug study within 30 day prior study entry Currently active chronic gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease malignancy require pharmacologic treatment , and/or opinion investigator , would affect study participation , safety , integrity result Use concomitant medication , include investigational , prescription , overthecounter product dietary supplement follow exception : aspirin , acetaminophen , ibuprofen , hormonal oral contraceptive Concomitant medication list must discontinue least 14 day study entry Currently active dermatitis urticaria diagnosis eczema psoriasis , History significant drug allergy ( i.e. , anaphylaxis and/or angioedema ) Subjects follow laboratory abnormality screen defined 2004 Division AIDS Table Grading Severity Adult Pediatric Adverse Events ( `` DAIDS grading table '' ) accordance normal range trial clinical laboratory : serum creatinine grade 1 great ( ≥ 1.1 x upper limit laboratory normal range ( ULN ) ) ; hemoglobin grade 1 great ( ≤ 10.9 g/dL ) ; platelet count grade 1 great ( ≤ 124.999 x 109/L ) ; absolute neutrophil count grade 1 great ( ≤ 1.3 x 109/L ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) grade 1 great ( ≥ 1.25 x ULN ) ; total bilirubin grade 1 great ( ≥ 1.1 x ULN ) , laboratory abnormality grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>dolutegravir</keyword>
	<keyword>simeprevir</keyword>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
</DOC>